Degradable Polymeric Carriers for Parenteral Controlled Drug Delivery

  • C. WischkeEmail author
  • S. P. Schwendeman
Part of the Advances in Delivery Science and Technology book series (ADST)


Drug loaded carriers from degradable polymers, namely, injectable microparticles, injectable in situ forming implants, and preformed implants, are established in the clinic for parenteral controlled drug delivery. This chapter provides an overview on several factors influencing release behavior such as drug properties, effects of environmental conditions, osmotically mediated mechanisms, and the selection of the carrier type. Moreover, degradation and erosion of the polymeric matrices are discussed in detail in view of their impact on drug release for different relevant polymer classes and groups of bioactive molecules. Additionally, carrier type-specific issues are included based on the knowledge gained to date from available parenteral controlled release products, as obtained from a comprehensive review of the scientific and patent literature. In particular, preparation techniques and related mechanisms, and both advantages and challenges associated with degradable polymer based delivery systems are described. Strategies to establish a continuous drug release are examined based on rational evaluation of specific polymer classes and carrier types.


Drug Release Water Uptake Release Profile Drug Carrier Polymer Degradation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T (1988) A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull 36:1095–1103PubMedGoogle Scholar
  2. 2.
    Hou Q, Chau DY, Pratoomsoot C, Tighe PJ, Dua HS, Shakesheff KM, Rose FR (2008) In situ gelling hydrogels incorporating microparticles as drug delivery carriers for regenerative medicine. J Pharm Sci 97:3972–3980PubMedGoogle Scholar
  3. 3.
    Harrison BS, Eberli D, Lee SJ, Atala A, Yoo JJ (2007) Oxygen producing biomaterials for tissue regeneration. Biomaterials 28:4628–4634PubMedGoogle Scholar
  4. 4.
    Wenk E, Meinel AJ, Wildy S, Merkle HP, Meinel L (2009) Microporous silk fibroin scaffolds embedding PLGA microparticles for controlled growth factor delivery in tissue engineering. Biomaterials 30:2571–2581PubMedGoogle Scholar
  5. 5.
    Tamada JA, Langer R (1993) Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci USA 90:552–556PubMedGoogle Scholar
  6. 6.
    Gopferich A (1996) Mechanisms of polymer degradation and erosion. Biomaterials 17:103–114PubMedGoogle Scholar
  7. 7.
    Gopferich A (1996) Polymer degradation and erosion: mechanisms and applications. Eur J Pharm Biopharm 42:1–11Google Scholar
  8. 8.
    Schwendeman SP, Cardamone M, Klibanov AM, Langer R, Brandon MR (1996) Stability of proteins and their delivery from biodegradable polymer microspheres. In: Cohen S, Bernstein H (eds) Microparticulate systems for the delivery of proteins and vaccines. Marcel Decker, New York, pp 1–49Google Scholar
  9. 9.
    Zhu G, Mallery SR, Schwendeman SP (2000) Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide). Nat Biotechnol 18:52–57PubMedGoogle Scholar
  10. 10.
    Perez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K (2002) Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J Pharm Pharmacol 54:301–313PubMedGoogle Scholar
  11. 11.
    Giteau A, Venier-Julienne MC, Aubert-Pouessel A, Benoit JP (2008) How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm 350:14–26PubMedGoogle Scholar
  12. 12.
    van der Walle CF, Sharma G, Ravi Kumar M (2009) Current approaches to stabilising and analysing proteins during microencapsulation in PLGA. Expert Opin Drug Deliv 6:177–186PubMedGoogle Scholar
  13. 13.
    Zhong Y, Zhang L, Ding AG, Shenderova A, Zhu G, Pei P, Chen RR, Mallery SR, Mooney DJ, Schwendeman SP (2007) Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/poly(DL-lactic-co-glycolic acid) implants. J Control Release 122:331–337PubMedGoogle Scholar
  14. 14.
    Desai KG, Mallery SR, Schwendeman SP (2008) Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur J Pharm Biopharm 70:187–198PubMedGoogle Scholar
  15. 15.
    Wang J, Wang BM, Schwendeman SP (2004) Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D, L-lactide-co-glycolide) microspheres. Biomaterials 25:1919–1927PubMedGoogle Scholar
  16. 16.
    Wischke C, Schwendeman SP (2008) Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364:298–327PubMedGoogle Scholar
  17. 17.
    Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR (2006) Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 114:359–368PubMedGoogle Scholar
  18. 18.
    Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M (2008) TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26:1626–1637PubMedGoogle Scholar
  19. 19.
    Arias JL, Gallardo V, Ruiz MA (2009) Engineering of poly(butylcyanoacrylate) nanoparticles for the enhancement of the antitumor activity of gemcitabine. Biomacromolecules 10:2310–2318Google Scholar
  20. 20.
    Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44:2115–2121PubMedGoogle Scholar
  21. 21.
    Wischke C, Neffe AT, Steuer S, Lendlein A (2009) Evaluation of a degradable shape-memory polymer network as matrix for controlled drug release. J Control Release 138:243–250PubMedGoogle Scholar
  22. 22.
    Wischke C, Neffe AT, Lendlein A (2010) Controlled drug release from shape-memory polymers. Adv Polym Sci 226:177–205Google Scholar
  23. 23.
    Wischke C, Lendlein A (2010) Shape-memory polymers as drug carriers – a multifunctional system. Pharm Res 27(4):527–529PubMedGoogle Scholar
  24. 24.
    Berkland C, King M, Cox A, Kim K, Pack DW (2002) Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release 82:137–147PubMedGoogle Scholar
  25. 25.
    Hutchinson FG (1986) Continuous release pharmaceutical compositions. European Patent EP 58 481Google Scholar
  26. 26.
    Klose D, Siepmann F, Willart JF, Descamps M, Siepmann J (2010) Drug release from PLGA-based microparticles: effects of the “microparticle:bulk fluid” ratio. Int J Pharm 383:123–131PubMedGoogle Scholar
  27. 27.
    Kulkarni A, Reiche J, Hartmann J, Kratz K, Lendlein A (2008) Selective enzymatic degradation of poly(epsilon-caprolactone) containing multiblock copolymers. Eur J Pharm Biopharm 68:46–56PubMedGoogle Scholar
  28. 28.
    Elkharraz K, Faisant N, Guse C, Siepmann F, Arica-Yegin B, Oger JM, Gust R, Goepferich A, Benoit JP, Siepmann J (2006) Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 314:127–136PubMedGoogle Scholar
  29. 29.
    Zhao ZJ, Wang Q, Zhang L, Liu YC (2007) A different diffusion mechanism for drug molecules in amorphous polymers. J Phys Chem B 111:4411–4416PubMedGoogle Scholar
  30. 30.
    Schwendeman SP, Tobio M, Joworowicz M, Alonso MJ, Langer R (1998) New strategies for the microencapsulation of tetanus vaccine. J Microencapsul 15:299–318PubMedGoogle Scholar
  31. 31.
    Domb AJ (1993) Degradable polymer blends.1. Screening of miscible polymers. J Polym Sci A Polym Chem 31:1973–1981Google Scholar
  32. 32.
    Matsumoto A, Matsukawa Y, Horikiri Y, Suzuki T (2006) Rupture and drug release characteristics of multi-reservoir type microspheres with poly(dl-lactide-co-glycolide) and poly(dl-lactide). Int J Pharm 327:110–116PubMedGoogle Scholar
  33. 33.
    Wang J (2000) Characterization of microsphere drug delivery systems during encapsulation and initial drug release. The Ohio State University, ColumbusGoogle Scholar
  34. 34.
    Kang J, Schwendeman SP (2007) Pore closing and opening in biodegradable polymers and their effect on the controlled release of proteins. Mol Pharm 4:104–118PubMedGoogle Scholar
  35. 35.
    Wool RP, Oconnor KM (1981) A theory of crack healing in polymers. J Appl Phys 52:5953–5963Google Scholar
  36. 36.
    Wool RP (2008) Self-healing materials: a review. Soft Matter 4:400–418Google Scholar
  37. 37.
    Wang J, Wang BM, Schwendeman SP (2002) Characterization of the initial burst release of a model peptide from poly(D, L-lactide-co-glycolide) microspheres. J Control Release 82:289–307PubMedGoogle Scholar
  38. 38.
    Heller J (1980) Controlled release of biologically-active compounds from bioerodible polymers. Biomaterials 1:51–57PubMedGoogle Scholar
  39. 39.
    Leonard F, Kulkarni RK, Brandes G, Nelson J, Cameron JJ (1966) Synthesis and degradation of poly (alkyl a-cyanoacrylates). J Appl Polym Sci 10:259–272Google Scholar
  40. 40.
    Ryan B, McCann G (1996) Novel sub-ceiling temperature rapid depolymerization-repolymerization reactions of cyanoacrylate polymers. Macromol Rapid Commun 17:217–227Google Scholar
  41. 41.
    Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, Speiser P (1984) Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5:65–68PubMedGoogle Scholar
  42. 42.
    Scherer D, Robinson JR, Kreuter J (1994) Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int J Pharm 101:165–168Google Scholar
  43. 43.
    Nicolas J, Couvreur P (2009) Synthesis of poly(alkyl cyanoacrylate)-based colloidal nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:111–127PubMedGoogle Scholar
  44. 44.
    Wischke C, Neffe AT, Steuer S, Lendlein A (2010) AB-polymer Networks with Cooligoester and Poly(n-butyl acrylate) Segments as a Multifunctional Matrix for Controlled Drug Release. Macromol Biosci 10:1063–1072PubMedGoogle Scholar
  45. 45.
    Augst AD, Kong HJ, Mooney DJ (2006) Alginate hydrogels as biomaterials. Macromol Biosci 6:623–633PubMedGoogle Scholar
  46. 46.
    Madaghiele M, Piccinno A, Saponaro M, Maffezzoli A, Sannino A (2009) Collagen- and gelatine-based films sealing vascular prostheses: evaluation of the degree of crosslinking for optimal blood impermeability. J Mater Sci Mater Med 20(10):1979–1989PubMedGoogle Scholar
  47. 47.
    Kraehenbuehl TP, Ferreira LS, Zammaretti P, Hubbell JA, Langer R (2009) Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials 30:4318–4324PubMedGoogle Scholar
  48. 48.
    Li SM, Garreau H, Vert M (1990) Structure-property relationships in the case of the degradation of massive poly(alpha -hydroxy acids) in aqueous media. Part 2 degradation of/actide-g/yco/ide copo/ymers. PLA37.5GA25 and PLA75GA25. J Mater Sci Mater Med 1:131–139Google Scholar
  49. 49.
    Park TG (1995) Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 16:1123–1130PubMedGoogle Scholar
  50. 50.
    Maniar M, Xie XD, Domb AJ (1990) Polyanhydrides. V. Branched polyanhydrides. Biomaterials 11:690–694PubMedGoogle Scholar
  51. 51.
    Kissel T, Brich Z, Bantle S, Lancranjan I, Nimmerfall F, Vit P (1991) Parenteral depot-systems on the basis of biodegradable polyesters. J Control Release 16:27–41Google Scholar
  52. 52.
    Jerome C, Lecomte P (2008) Recent advances in the synthesis of aliphatic polyesters by ring-opening polymerization. Adv Drug Deliv Rev 60:1056–1076PubMedGoogle Scholar
  53. 53.
    Ding AG, Schwendeman SP (2004) Determination of water-soluble acid distribution in poly(lactide-co-glycolide). J Pharm Sci 93:322–331PubMedGoogle Scholar
  54. 54.
    Siepmann J, Elkharraz K, Siepmann F, Klose D (2005) How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules 6:2312–2319PubMedGoogle Scholar
  55. 55.
    Li L, Schwendeman SP (2005) Mapping neutral microclimate pH in PLGA microspheres. J Control Release 101:163–173PubMedGoogle Scholar
  56. 56.
    Li SM, Garreau H, Vert M (1990) Structure-property relationships in the case of the degradation of massive aliphatic poly-(alpha-hydroxy acids) in aqueous media. Part 1 poly(dl-lactic acid). J Mater Sci Mater Med 1:123–130Google Scholar
  57. 57.
    Li S (1999) Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 48:342–353PubMedGoogle Scholar
  58. 58.
    Lu L, Garcia CA, Mikos AG (1999) In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res 46:236–244PubMedGoogle Scholar
  59. 59.
    von Burkersroda F, Schedl L, Gopferich A (2002) Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 23:4221–4231Google Scholar
  60. 60.
    Rothstein SN, Federspiel WJ, Little SR (2009) A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices. Biomaterials 30:1657–1664PubMedGoogle Scholar
  61. 61.
    Furr BJA, Hutchinson FG (1992) A biodegradable delivery system for peptides: preclinical experience with the gonadotrophin-releasing hormone agonist Zoladex. J Control Release 21:117–128Google Scholar
  62. 62.
    Husmann M, Schenderlein S, Luck M, Lindner H, Kleinebudde P (2002) Polymer erosion in PLGA microparticles produced by phase separation method. Int J Pharm 242:277–280PubMedGoogle Scholar
  63. 63.
    Grizzi I, Garreau H, Li S, Vert M (1995) Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 16:305–311PubMedGoogle Scholar
  64. 64.
    Witschi C, Doelker E (1998) Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing. J Control Release 51:327–341PubMedGoogle Scholar
  65. 65.
    Bhardwaj R, Blanchard J (1998) In vitro characterization and in vivo release profile of a poly(D, L-lactide-co-glycolide)-based implant delivery system for the alpha-MSH analog, melanotan-I. Int J Pharm 170:109–117Google Scholar
  66. 66.
    Liggins RT, Burt HM (2001) Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int J Pharm 222:19–33PubMedGoogle Scholar
  67. 67.
    Vidil C, Braud C, Garreau H, Vert M (1995) Monitoring of the poly(D, L-lactic acid) degradation by-products by capillary zone electrophoresis. J Chromatogr A 711:323–329Google Scholar
  68. 68.
    Joshi A, Himmelstein KJ (1990) Kinetics of controlled release from acid catalyzed polymeric matrices. Polym Prepr 31:175–176Google Scholar
  69. 69.
    Gopferich A, Tessmar J (2002) Polyanhydride degradation and erosion. Adv Drug Deliv Rev 54:911–931PubMedGoogle Scholar
  70. 70.
    Xu XJ, Sy JC, Shastri VP (2006) Towards developing surface eroding poly(alpha-hydroxy acids). Biomaterials 27:3021–3030PubMedGoogle Scholar
  71. 71.
    Alexis F (2005) Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly (lactic acid)-co-(glycolic acid). Polym Int 54:36–46Google Scholar
  72. 72.
    Zolnik BS, Burgess DJ (2008) Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 127:137–145PubMedGoogle Scholar
  73. 73.
    Hakkarainen M (2002) Aliphatic polyesters: abiotic and biotic degradation and degradation products. Adv Polym Sci 157:113–138Google Scholar
  74. 74.
    Pitt CG, Hendren RW, Schindler A, Woodward SC (1984) The enzymatic surface erosion of aliphatic polyesters. J Control Release 1:3–14Google Scholar
  75. 75.
    Liu F, Zhao ZX, Yang J, Wei J, Li SM (2009) Enzyme-catalyzed degradation of poly(L-lactide)/poly(epsilon-caprolactone) diblock, triblock and four-armed copolymers. Polym Degrad Stabil 94:227–233Google Scholar
  76. 76.
    Desai KG, Mallery SR, Schwendeman SP (2008) Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor. Pharm Res 25:586–597PubMedGoogle Scholar
  77. 77.
    Maulding HV, Tice TR, Cowar DR, Fong JW, Pearson JE, Nazareno JP (1986) Biodegradable microcapsules: acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament. J Control Release 3:103–117Google Scholar
  78. 78.
    Wang L, Venkatraman S, Kleiner L (2004) Drug release from injectable depots: two different in vitro mechanisms. J Control Release 99:207–216PubMedGoogle Scholar
  79. 79.
    Cha Y, Pitt CG (1988) A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules. J Control Release 8:69–78Google Scholar
  80. 80.
    Cha Y, Pitt CG (1989) The acceleration of degradation controlled drug delivery from polyester microspheres. J Control Release 8:259–265Google Scholar
  81. 81.
    Siegel SJ, Kahn JB, Metzger K, Winey KI, Werner K, Dan N (2006) Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm 64:287–293PubMedGoogle Scholar
  82. 82.
    Heller J, Barr J (2005) Biochronomer technology. Expert Opin Drug Deliv 2:169–183PubMedGoogle Scholar
  83. 83.
    APF530 study (2009) APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (NCT00343460). U.S. National Institutes of Health.
  84. 84.
    AP Pharma (2010) Press release: A.P. Pharma Receives FDA Complete Response Letter for APF530. Accessed 18 Jun 2010
  85. 85.
    Packhaeuser CB, Schnieders J, Oster CG, Kissel T (2004) In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 58:445–455PubMedGoogle Scholar
  86. 86.
    Exner AA, Saidel GM (2008) Drug-eluting polymer implants in cancer therapy. Expert Opin Drug Deliv 5:775–788PubMedGoogle Scholar
  87. 87.
    Wykrzykowska JJ, Onuma Y, Serruys PW (2009) Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin Drug Deliv 6:113–126PubMedGoogle Scholar
  88. 88.
    Su S-H (2007) Mini Review of the fully biodegradable polymeric stents. Recent Pat Eng 1:244–250Google Scholar
  89. 89.
    ANZHSN (2007) Biodegradable stents for coronary artery disease. Australian Government, Department of Health and Aging.
  90. 90.
    Ramcharitar S, Serruys PW (2008) Fully biodegradable coronary stents: progress to date. Am J Cardiovasc Drugs 8:305–314PubMedGoogle Scholar
  91. 91.
    Weber N, Pesnell A, Bolikal D, Zeltinger J, Kohn J (2007) Viscoelastic properties of fibrinogen adsorbed to the surface of biomaterials used in blood-contacting medical devices. Langmuir 23:3298–3304PubMedGoogle Scholar
  92. 92.
    Lendlein A, Behl A, Hiebl B, Wischke C (2010) Shape-memory polymers as technology platform for biomedical applications. Expert Rev Med Dev 7:357–379Google Scholar
  93. 93.
    Okada H, Ogawa Y, Yashiki T (1987) Prolonged release microcapsule and its production. United States Patent US 4,652,441Google Scholar
  94. 94.
    Castellanos IJ, Cuadrado WO, Griebenow K (2001) Prevention of structural perturbations and aggregation upon encapsulation of bovine serum albumin into poly(lactide-co-glycolide) micropheres using the solid-in-oil-in water technique. J Pharm Pharmacol 53:1099–1107PubMedGoogle Scholar
  95. 95.
    Carrasquillo KG, Carro JC, Alejandro A, Toro DD, Griebenow K (2001) Reduction of structural perturbations in bovine serum albumin by non-aqueous microencapsulation. J Pharm Pharmacol 53:115–120PubMedGoogle Scholar
  96. 96.
    Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJ, Putney SD (1996) A month-long effect from a single injection of microencapsulated human growth hormone. Nat Med 2:795–799PubMedGoogle Scholar
  97. 97.
    Wakiyama N, Juni K, Nakano M (1981) Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull 29:3363–3368PubMedGoogle Scholar
  98. 98.
    Dean RL (2005) The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence. Front Biosci 10:643–655PubMedGoogle Scholar
  99. 99.
    Sah H, Lee B (2006) Development of new microencapsulation techniques useful for the preparation of PLGA microspheres. Macromol Rapid Commun 27:1845–1851Google Scholar
  100. 100.
    Wada R, Hyon SH, Ikada Y (1990) Lactic-acid oligomer microspheres containing hydrophilic drugs. J Pharm Sci 79:919–924PubMedGoogle Scholar
  101. 101.
    Bodmeier R, Chen HG (1988) Preparation of biodegradable Poly (+/−) lactide microparticles using a spray-drying technique. J Pharm Pharmacol 40:754–757PubMedGoogle Scholar
  102. 102.
    Leelarasamee N, Howard SA, Malanga CJ, Luzzi LA, Hogan TF, Kandzari SJ, Ma JK (1986) Kinetics of drug release from polylactic acid-hydrocortisone microcapsules. J Microencapsul 3:171–179PubMedGoogle Scholar
  103. 103.
    Lill N, Sandow J (1995) Langwirkende bioabbaubare Mikropartikel und ein Verfahren zur Herstellung. European PatentGoogle Scholar
  104. 104.
    Bodmer D, Fong JW, Kissel T, Maulding HV, Nagele O, Pearson JE (1996) Sustained release formulations of water soluble peptides. United States Patent US 5,538,739Google Scholar
  105. 105.
    Kissel T, Maretschek S, Packhaeuser CB, Schnieders J, Seidel N (2006) Microencapsulation techniques for parenteral depot systems and their application in the pharmaceutical industry. In: Benita S (ed) Microencapsulation: methods and industrial application. CRC, Boca Raton, FLGoogle Scholar
  106. 106.
    Smith A, Hunneyball IM (1986) Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 30:215–220Google Scholar
  107. 107.
    Mishima K (2008) Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas. Adv Drug Deliv Rev 60:411–432PubMedGoogle Scholar
  108. 108.
    Williams JR, Clifford AA, Al-Saidi SH (2002) Supercritical fluids and their applications in biotechnology and related areas. Mol Biotechnol 22:263–286PubMedGoogle Scholar
  109. 109.
    Wischke C, Borchert HH (2006) Influence of the primary emulsification procedure on the characteristics of small protein-loaded PLGA microparticles for antigen delivery. J Microencapsul 23:435–448PubMedGoogle Scholar
  110. 110.
    Okada H (1997) One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 28:43–70PubMedGoogle Scholar
  111. 111.
    Zhou T, Lewis H, Foster RE, Schwendeman SP (1998) Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Release 55:281–295PubMedGoogle Scholar
  112. 112.
    Ghalanbor Z, Korber M, Bodmeier R (2010) Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Pharm Res 27:371–379PubMedGoogle Scholar
  113. 113.
    Breitenbach J (2002) Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm 54:107–117PubMedGoogle Scholar
  114. 114.
    Rothen-Weinhold A, Schwach-Abdellaoui K, Barr J, Ng SY, Shen HR, Gurny R, Heller J (2001) Release of BSA from poly(ortho ester) extruded thin strands. J Control Release 71:31–37PubMedGoogle Scholar
  115. 115.
    Li LC, Deng J, Stephens D (2002) Polyanhydride implant for antibiotic delivery – from the bench to the clinic. Adv Drug Deliv Rev 54:963–986PubMedGoogle Scholar
  116. 116.
    Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76:640–647PubMedGoogle Scholar
  117. 117.
    Chasin B, Hollenbeck G, Brem H, Grossman S, Colvin M, Langer R (1990) Interstitial drug therapy for brain tumors: a case study. Drug Dev Ind Pharm 16:2579–2594Google Scholar
  118. 118.
    Akbari H, D’Emanuele A, Attwood D (1998) Effect of fabrication technique on the erosion characteristics of polyanhydride matrices. Pharm Dev Technol 3:251–259PubMedGoogle Scholar
  119. 119.
    Laurencin CT, Ibim SEM, Langer RS (1995) Poly(anhydrides). In: Hollinger JO (ed) Biomedical applications of synthetic biodegradable polymers. CRC, Boca Raton, FL, pp 59–102Google Scholar
  120. 120.
    Weiler W, Gogolewski S (1996) Enhancement of the mechanical properties of polylactides by solid-state extrusion.1. Poly(D-lactide). Biomaterials 17:529–535PubMedGoogle Scholar
  121. 121.
    Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK (1993) The effect of melt-processing on the degradation of selected polyhydroxyacids – polylactides, polyhydroxybutyrate, and polyhydroxybutyrate-co-valerates. Polym Degrad Stabil 40:313–322Google Scholar
  122. 122.
    Rothen-Weinhold A, Besseghir K, Vuaridel E, Sublet E, Oudry N, Gurny R (1999) Stability studies of a somatostatin analogue in biodegradable implants. Int J Pharm 178:213–221PubMedGoogle Scholar
  123. 123.
    Leighton D, Acrivos A (1987) The shear-induced migration of particles in concentrated suspensions. J Fluid Mech 181:415–439Google Scholar
  124. 124.
    Nott PR, Brady JF (1994) Pressure-driven flow of suspensions – simulation and theory. J Fluid Mech 275:157–199Google Scholar
  125. 125.
    Deng J, Li L, Stephens D, Tian Y, Robinson D (2004) Effect of postmolding heat treatment on in vitro properties of a polyanhydride implant containing gentamicin sulfate. Drug Dev Ind Pharm 30:341–346PubMedGoogle Scholar
  126. 126.
    Choi SH, Park TG (2000) Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres. Int J Pharm 203:193–202PubMedGoogle Scholar
  127. 127.
    Schwendeman SP (2002) Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73–98PubMedGoogle Scholar
  128. 128.
    Zhu G, Schwendeman SP (2000) Stabilization of proteins encapsulated in cylindrical poly(lactide-co-glycolide) implants: mechanism of stabilization by basic additives. Pharm Res 17:351–357PubMedGoogle Scholar
  129. 129.
    Kang JC, Schwendeman SP (2002) Comparison of the effects of Mg(OH)(2) and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D, L-lactide-co-glycolide) implants. Biomaterials 23:239–245PubMedGoogle Scholar
  130. 130.
    Jiang WL, Schwendeman SP (2008) Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Mol Pharm 5:808–817PubMedGoogle Scholar
  131. 131.
    Zhang Y, Zale S, Sawyer L, Bernstein H (1997) Effects of metal salts on poly(DL-lactide-co-glycolide) polymer hydrolysis. J Biomed Mater Res 34:531–538PubMedGoogle Scholar
  132. 132.
    Sandow J, von Rechenberg W, Seidel H, Keil M (1989) Experimental studies on tissue tolerance and on biodegradation of polylactide/glycolide-buserelin implants in rats. In: Aumüller G (ed) New aspects in the regulation of prostatic function. W. Zuckerschwerdt Verlag GmbH, Munich, pp 157–166Google Scholar
  133. 133.
    Siepmann J, Gopferich A (2001) Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 48:229–247PubMedGoogle Scholar
  134. 134.
    Lin SH, Kleinberg LR (2008) Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8:343–359PubMedGoogle Scholar
  135. 135.
    Dang W, Daviau T, Brem H (1996) Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 13:683–691PubMedGoogle Scholar
  136. 136.
    Kumar N, Langer RS, Domb AJ (2002) Polyanhydrides: an overview. Adv Drug Deliv Rev 54:889–910PubMedGoogle Scholar
  137. 137.
    Domb AJ, Israel ZH, Elmalak O, Teomim D, Bentolila A (1999) Preparation and characterization of carmustine loaded polyanhydride wafers for treating brain tumors. Pharm Res 16:762–765PubMedGoogle Scholar
  138. 138.
    Dang WB, Daviau T, Ying P, Zhao Y, Nowotnik D, Clow CS, Tyler B, Brem H (1996) Effects of GLIADEL(R) wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release 42:83–92Google Scholar
  139. 139.
    Jeong B, Bae YH, Lee DS, Kim SW (1997) Biodegradable block copolymers as injectable drug-delivery systems. Nature 388:860–862PubMedGoogle Scholar
  140. 140.
    Couffin-Hoarau AC, Motulsky A, Delmas P, Leroux JC (2004) In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives. Pharm Res 21:454–457PubMedGoogle Scholar
  141. 141.
    Motulsky A, Lafleur M, Couffin-Hoarau AC, Hoarau D, Boury F, Benoit JP, Leroux JC (2005) Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants. Biomaterials 26:6242–6253PubMedGoogle Scholar
  142. 142.
    Jeong B, Bae YH, Kim SW (1999) Thermoreversible gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions. Macromolecules 32:7064–7069Google Scholar
  143. 143.
    Gong C, Shi S, Wu L, Gou M, Yin Q, Guo Q, Dong P, Zhang F, Luo F, Zhao X, Wei Y, Qian Z (2009) Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part 2: sol-gel-sol transition and drug delivery behavior. Acta Biomater 5:3358–3370PubMedGoogle Scholar
  144. 144.
    Sarkar N (1979) Thermal gelation properties of methyl and hydroxypropyl methylcellulose. J Appl Polym Sci 24:1073–1087Google Scholar
  145. 145.
    Tate MC, Shear DA, Hoffman SW, Stein DG, LaPlaca MC (2001) Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 22:1113–1123PubMedGoogle Scholar
  146. 146.
    Park KM, Shin YM, Joung YK, Shin H, Park KD (2010) In situ forming hydrogels based on tyramine conjugated 4-Arm-PPO-PEO via enzymatic oxidative reaction. Biomacromolecules 11(3):706–712PubMedGoogle Scholar
  147. 147.
    Slepian MJ, Hubbell JA (1997) Polymeric endoluminal gel paving: hydrogel systems for local barrier creation and site-specific drug delivery. Adv Drug Deliv Rev 24:11–30Google Scholar
  148. 148.
    Ramakumar S, Roberts WW, Fugita OE, Colegrove P, Nicol TM, Jarrett TW, Kavoussi LR, Slepian MJ (2002) Local hemostasis during laparoscopic partial nephrectomy using biodegradable hydrogels: initial porcine results. J Endourol 16:489–494PubMedGoogle Scholar
  149. 149.
    Qiu B, Stefanos S, Ma JL, Lalloo A, Perry BA, Leibowitz MJ, Sinko PJ, Stein S (2003) A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 24:11–18PubMedGoogle Scholar
  150. 150.
    Cohen S, Lobel E, Trevgoda A, Peled Y (1997) A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 44:201–208Google Scholar
  151. 151.
    Packhaeuser CB, Kissel T (2007) On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles. J Control Release 123:131–140PubMedGoogle Scholar
  152. 152.
    Heller J, Barr J, Ng SY, Shen HR, Schwach-Abdellaoui K, Gurny R, Vivien-Castioni N, Loup PJ, Baehni P, Mombelli A (2002) Development and applications of injectable poly(ortho esters) for pain control and periodontal treatment. Biomaterials 23:4397–4404Google Scholar
  153. 153.
    Barr J, Woodburn KW, Ng SY, Shen HR, Heller J (2002) Post surgical pain management with poly(ortho esters). Adv Drug Deliv Rev 54:1041–1048PubMedGoogle Scholar
  154. 154.
    Hatefi A, Amsden B (2002) Biodegradable injectable in situ forming drug delivery systems. J Control Release 80:9–28PubMedGoogle Scholar
  155. 155.
    Bezwada RS (1995) Liquid copolymers of epsilon-caprolactone and lactide. United States Patent US 5,422,033Google Scholar
  156. 156.
    Bezwada RS, Arnold SC, Shalaby SW, Williams BL (1997) Liquid absorbable polymers for parenteral applications. United States Patent US 5,653,992Google Scholar
  157. 157.
    Jain JP, Modi S, Kumar N (2008) Hydroxy fatty acid based polyanhydride as drug delivery system: synthesis, characterization, in vitro degradation, drug release, and biocompatibility. J Biomed Mater Res A 84A:740–752Google Scholar
  158. 158.
    Dunn RL, English JP, Cowsar DR, Vanderbilt DP (1990) Biodegradable in situ forming implants and methods of producing the same. United States Patent US 4,938,763Google Scholar
  159. 159.
    Dunn RL, Tipton AJ (1997) Polymeric compositions useful as controlled release implants. United States Patent US 7,702,716Google Scholar
  160. 160.
    Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani M, Palmer D, Infeld MH, Malick AW (1993) A biodegradable injectable implant for delivering micromolecules and macromolecules using poly(lactic-co-glycolic) acid (plga) copolymers. J Control Release 27:139–147Google Scholar
  161. 161.
    Brodbeck KJ, Gaynor-Duarte AT, Shen TT (2000) Gel compositions and methods. United States Patent US 6,130,200Google Scholar
  162. 162.
    Tipton AJ (1999) High viscosity liquid controlled delivery system as a device. United States Patent US 5,968,542Google Scholar
  163. 163.
    Burns PJ, Gibson JW, Tipton AJ (2000) Compositions suitable for controlled release of the hormone GNRH and its analogs. United States Patent US 6,051,558Google Scholar
  164. 164.
    Bodmeier R (1998) Verfahren zur in-situ Herstellung von Partikeln. German Patent Application Publication DE 197 24 784Google Scholar
  165. 165.
    Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R (2001) Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm 212:11–18PubMedGoogle Scholar
  166. 166.
    Rungseevijitprapa W, Bodmeier R (2009) Injectability of biodegradable in situ forming microparticle systems (ISM). Eur J Pharm Sci 36:524–531PubMedGoogle Scholar
  167. 167.
    Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH (2000) Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm 50:257–262PubMedGoogle Scholar
  168. 168.
    Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH (2000) Comparison of various injectable protein-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices: in-situ-formed implant versus in-situ-formed microspheres versus isolated microspheres. Pharm Dev Technol 5:201–207PubMedGoogle Scholar
  169. 169.
    Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH (2000) Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system. J Microencapsul 17:343–362PubMedGoogle Scholar
  170. 170.
    Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL (1999) Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res 45:231–239PubMedGoogle Scholar
  171. 171.
    Graham PD, Brodbeck KJ, McHugh AJ (1999) Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release 58:233–245PubMedGoogle Scholar
  172. 172.
    Brodbeck KJ, DesNoyer JR, McHugh AJ (1999) Phase inversion dynamics of PLGA solutions related to drug delivery – Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release 62:333–344PubMedGoogle Scholar
  173. 173.
    Astaneh R, Erfan M, Moghimi H, Mobedi H (2009) Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci 98:135–145PubMedGoogle Scholar
  174. 174.
    Brodbeck KJ, Pushpala S, McHugh AJ (1999) Sustained release of human growth hormone from PLGA solution depots. Pharm Res 16:1825–1829PubMedGoogle Scholar
  175. 175.
    Chen SB, Singh J (2005) Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation. Int J Pharm 295:183–190PubMedGoogle Scholar
  176. 176.
    Singh S, Singh J (2007) Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 328:42–48PubMedGoogle Scholar
  177. 177.
    Kang F, Singh J (2005) In vitro release of insulin and biocompatibility of in situ forming gel systems. Int J Pharm 304:83–90PubMedGoogle Scholar
  178. 178.
    Singh S, Singh J (2004) Controlled release of a model protein lysozyme from phase sensitive smart polymer systems. Int J Pharm 271:189–196PubMedGoogle Scholar
  179. 179.
    Yewey GL, Duysen ED, Cox SM, Dunn RL (1997) Delivery of proteins from a controlled release injectable implant. In: Sanders LM, Hendren RW (eds) Protein delivery: physical systems. Plenum, New York, pp 93–117Google Scholar
  180. 180.
    Dunn RL, Yewey GL, Fujita SM, Josephs KR, Whitman SL, Southard GL, Dernell WS, Straw RC, Withrow SJ, Powers BE (1996) Sustained release of cisplatin in dogs from an injectable implant delivery system. J Bioact Compat Pol 11:286–300Google Scholar
  181. 181.
    Fang F, Gong CY, Dong PW, Fu SZ, Gu YC, Guo G, Zhao X, Wei YQ, Qian ZY (2009) Acute toxicity evaluation of in situ gel-forming controlled drug delivery system based on biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Biomed Mater 4:025002PubMedGoogle Scholar
  182. 182.
    Schoenhammer K, Petersen H, Guethlein F, Goepferich A (2009) Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability. Int J Pharm 371:33–39PubMedGoogle Scholar
  183. 183.
    Schoenhammer K, Petersen H, Guethlein F, Goepferich A (2009) Poly(ethyleneglycol) 500 dimethylether as novel solvent for injectable in situ forming depots. Pharm Res 26:2568–2577PubMedGoogle Scholar
  184. 184.
    Eliaz RE, Kost J (2000) Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res 50:388–396PubMedGoogle Scholar
  185. 185.
    Krebs MD, Sutter KA, Lin ASP, Guldberg RE, Alsberg E (2009) Injectable poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering. Acta Biomater 5:2847–2859PubMedGoogle Scholar
  186. 186.
    Shively ML, Coonts BA, Renner WD, Southard J, Bennett AT (1995) Physicochemical characterization of a polymeric injectable implant delivery system. J Control Release 33:237–243Google Scholar
  187. 187.
    Ravivarapu HB, Moyer KL, Dunn RL (2000) Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm 194:181–191PubMedGoogle Scholar
  188. 188.
    Kempe S, Metz H, Pereira PG, Mader K (2010) Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur J Pharm Biopharm 74:102–108PubMedGoogle Scholar
  189. 189.
    Kempe S, Metz H, Mader K (2008) Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release 130:220–225PubMedGoogle Scholar
  190. 190.
    Solorio L, Babin BM, Patel RB, Mach J, Azar N, Exner AA (2010) Noninvasive characterization of in situ forming implants using diagnostic ultrasound. J Control Release 143(2):183–190PubMedGoogle Scholar
  191. 191.
    Miyajima M, Koshika A, Okada J, Ikeda M, Nishimura K (1997) Effect of polymer crystallinity on papaverine release from poly (L-lactic acid) matrix. J Control Release 49:207–215Google Scholar
  192. 192.
    DesNoyer JR, McHugh AJ (2001) Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. J Control Release 70:285–294PubMedGoogle Scholar
  193. 193.
    Wang L, Kleiner L, Venkatraman S (2003) Structure formation in injectable poly(lactide-co-glycolide) depots. J Control Release 90:345–354PubMedGoogle Scholar
  194. 194.
    Astaneh R, Nafissi-Varcheh N, Erfan M (2007) Zinc-leuprolide complex: preparation, physicochemical characterization and release behaviour from in situ forming implant. J Pept Sci 13:649–654PubMedGoogle Scholar
  195. 195.
    Dudeck O, Jordan O, Hoffmann KT, Okuducu AF, Tesmer K, Kreuzer-Nagy T, Rufenacht DA, Doelker E, Felix R (2006) Organic solvents as vehicles for precipitating liquid embolics: a comparative angiotoxicity study with superselective injections of swine rete mirabile. Am J Neuroradiol 27:1900–1906PubMedGoogle Scholar
  196. 196.
    AGL9909 study (2000) A six-month, open label, fixed dose study to evaluate the safety, tolerance, pharmacokinetics and endocrine efficacy of two doses of LA-2550 22.5mg in patients with advanced prostate cancer, Eligard® product information. Accessed 23 Jan 2008
  197. 197.
    Cox MC, Scripture CD, Figg WD (2005) Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Rev Anticancer Ther 5:605–611PubMedGoogle Scholar
  198. 198.
    Kim TS, Klimpel H, Fiehn W, Eickholz P (2004) Comparison of the pharmacokinetic profiles of two locally administered doxycycline gels in crevicular fluid and saliva. J Clin Periodontol 31:286–292PubMedGoogle Scholar
  199. 199.
    Southard GL, Dunn RL, Garrett S (1998) The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs 7:1483–1491PubMedGoogle Scholar
  200. 200.
    Langer R (1980) Polymeric delivery systems for controlled drug release. Chem Eng Commun 6:1–48Google Scholar
  201. 201.
    Sanders LM, McRae GI, Vitale KM, Kell BA (1985) Controlled delivery of an LHRH analogue from biodegradable injectable microspheres. J Control Release 2:187–195Google Scholar
  202. 202.
    Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, Lewis DH (1984) Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d, l-lactide-co-glycolide) microspheres. J Pharm Sci 73:1294–1297PubMedGoogle Scholar
  203. 203.
    Allison SD (2008) Analysis of initial burst in PLGA microparticles. Expert Opin Drug Deliv 5:615–628PubMedGoogle Scholar
  204. 204.
    Jalil R, Nixon JR (1989) Microencapsulation using poly(L-lactic acid). I: microcapsule properties affected by the preparative technique. J Microencapsul 6:473–484PubMedGoogle Scholar
  205. 205.
    Wischke C, Neffe AT, Steuer S, Lendlein A (2010) Comparing techniques for drug loading of shape-memory polymer networks-effect on their functionalities. Eur J Pharm Sci. doi: 10.1016/j.ejps.2010.06.003
  206. 206.
    Yeo Y, Park K (2004) Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 27:1–12PubMedGoogle Scholar
  207. 207.
    Bodmeier R, McGinity JW (1987) The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method. Pharm Res 4:465–471PubMedGoogle Scholar
  208. 208.
    Kang JC, Schwendeman SP (2003) Determination of diffusion coefficient of a small hydrophobic probe in poly(lactide-co-glycolide) microparticles by laser scanning confocal microscopy. Macromolecules 36:1324–1330Google Scholar
  209. 209.
    Luan X, Bodmeier R (2006) In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters. Eur J Pharm Sci 27:143–149PubMedGoogle Scholar
  210. 210.
    Bodmeier R, Oh KH, Chen H (1989) The effect of the addition of low-molecular weight poly(Dl-Lactide) on drug release from biodegradable poly(Dl-Lactide) drug delivery systems. Int J Pharm 51:1–8Google Scholar
  211. 211.
    Lavelle EC, Yeh MK, Coombes AG, Davis SS (1999) The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 17:512–529PubMedGoogle Scholar
  212. 212.
    Jiang WL, Schwendeman SP (2001) Stabilization and controlled release of bovine serum albumin encapsulated in poly(D, L-lactide) and poly(ethylene glycol) microsphere blends. Pharm Res 18:878–885PubMedGoogle Scholar
  213. 213.
    Ravivarapu HB, Burton K, DeLuca PP (2000) Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 50:263–270PubMedGoogle Scholar
  214. 214.
    Langer RS, Peppas NA (1981) Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 2:201–214PubMedGoogle Scholar
  215. 215.
    Okada H, Heya T, Ogawa Y, Toguchi H, Shimamoto T (1991) Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate. Pharm Res 8:584–587PubMedGoogle Scholar
  216. 216.
    Chia HH, Yang YY, Chung TS, Ng S, Heller J (2001) Auto-catalyzed poly(ortho ester) microspheres: a study of their erosion and drug release mechanism. J Control Release 75:11–25PubMedGoogle Scholar
  217. 217.
    Kent JS, Sanders L, Tice TR, Lewis DH (1984) Microencapsulation of the peptide narfalin acetate for controlled release. In: Zatuchni GI, Goldsmith A, Shelton JD, Sciarra JJ (eds) Long-acting contraceptive delivery systems. Harper & Row, Philadelphia, pp 169–179Google Scholar
  218. 218.
    Bodmer D, Kissel T, Traechslin E (1992) Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J Control Release 21:129–137Google Scholar
  219. 219.
    Bodmer D, Fong JW, Kissel T, Maulding HV, Nagele O, Pearson JE (1996) Octreotidepamoat und dessen Verwendung zur Herstellung von pharmazeutischen Formulierungen. Swiss Patent CH 686 252Google Scholar
  220. 220.
    Bodmer D, Fong JW, Kissel T, Maulding HV, Nagele O, Pearson JE (1997) Sustained release formulations of water soluble peptides. United States Patent US 5,639,480Google Scholar
  221. 221.
    Lambert O, Ausborn M, Petersen H, Löffler R, Bonny J-D (2004) Pharmaceutical composition comprising microparticles. International Publication WO 2004/045633Google Scholar
  222. 222.
    Petersen H, Ahlheimer M (2007) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers. International Publication WO 2007/071395Google Scholar
  223. 223.
    Pellet M, Roume C (2002) Sustained release compositions and the process for their preparation. US Patent US 6,475,507Google Scholar
  224. 224.
    Okada H, Ionoue Y, Ogawa Y, Toguchi H (1992) Three-month release injectable microspheres of leuprolin acetate. Proc Int Symp Control Rel Bioact Mater 19:52Google Scholar
  225. 225.
    Okada H, Yamamoto M, Heya T, Inoue Y, Kamei S, Ogawa Y, Toguchi H (1994) Drug-delivery using biodegradable microspheres. J Control Release 28:121–129Google Scholar
  226. 226.
    Ogawa Y, Yamamoto M, Takada S, Okada H, Shimamoto T (1988) Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer. Chem Pharm Bull 36:1502–1507PubMedGoogle Scholar
  227. 227.
    Okada H, Heya T, Ogawa Y, Shimamoto T (1988) One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J Pharmacol Exp Ther 244:744–750PubMedGoogle Scholar
  228. 228.
    Ogawa Y, Okada H, Heya T, Shimamoto T (1989) Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 41:439–444PubMedGoogle Scholar
  229. 229.
    Ogawa Y (1992) Monthly microcapsule-depot form of LHRH agonist, leuprolide acetate (Enantone® Depot): formulation and pharmacokinetics in animals. Eur J Hosp Pharm 2:120–127Google Scholar
  230. 230.
    Yamamoto M, Takada S, Ogawa Y (1994) Sustained release microcapsule. United States Patent US 5,330,767Google Scholar
  231. 231.
    Takechi N, Ohtani S, Nagai A (2002) Production of microspheres. European Patent EP 779 072Google Scholar
  232. 232.
    Nerlich B, Mank R, Gustafsson J, Hörig J, Köchling W (1996) Mikroverkapselung wasserlöslicher Wirkstoffe. European Patent EP 579 347Google Scholar
  233. 233.
    Mank R, Gustafsson J, Hörig J, Köchling W, Nerlich B (1996) Microencapsulation of water-soluble medicaments. United States Patent US 5,503,851Google Scholar
  234. 234.
    Klippel KF, Winkler CJ, Jocham D, Rubben H, Moser B, Gulati A (1999) Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma. Urologe A 38:270–275PubMedGoogle Scholar
  235. 235.
    Orsolini P (1992) Method for preparing a pharmaceutical composition in the form of microparticles. United States Patent US 5,134,122Google Scholar
  236. 236.
    Orsolini P (1993) Pharmaceutical composition in the form of microparticles. United States Patent US 5,225,205Google Scholar
  237. 237.
    Bartus RT, Emerich DF, Hotz J, Blaustein M, Dean RL, Perdomo B, Basile AS (2003) Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 28:1973–1982PubMedGoogle Scholar
  238. 238.
    Rickey ME, Ramstack JM, Lewis DH, Mesens J (1998) Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent. United Staes Patent US 5,792,477Google Scholar
  239. 239.
    Wright SG, Rickley ME, Ramstack JM, Lyons SL, Hotz JM (2001) Method for preparing microparticles having a selected polymer molecular weight. United States Patent US 6,264,987Google Scholar
  240. 240.
    Mesens J, Rickey ME, Atkins TJ (2003) Microencapsulated 3-Piperidinyl substituted 1,2-benzisooxazoles and 1,2-benzisothiazoles. United States Patent US 6,544,559Google Scholar
  241. 241.
    Ramstack JM, Riley MG, Zale SE, Hotz JM, Johnson OL (2003) Preparation of injectable suspensions having improved injectability. United States Patent US 6,667,061Google Scholar
  242. 242.
    Lyons SL, Wright SG (2004) Apparatus and method for preparing microparticles. United States Patent US 6,713,090Google Scholar
  243. 243.
    Lyons SL, Wright SG (2005) Method and apparatus for preparing microparticles using in-line solvent extraction. United States Patent US 6,939,033Google Scholar
  244. 244.
    Lawter JR, Lanzilotti MG (1996) Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease. United States Patent US 5,500,228Google Scholar
  245. 245.
    Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA (2005) Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48:1380–1385PubMedGoogle Scholar
  246. 246.
    Iwamoto K, Nasu R, Yamamura A, Kothare PA, Mace K, Wolka AM, Linnebjerg H (2009) Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 56:951–962PubMedGoogle Scholar
  247. 247.
    Sandow J, Seidel HR, Krauss B, Jerabek-Sandow G (1987) Pharmacokinetics of LHRH agonist in different deliver systems and the relation to endocrine function. In: Klijn JGM (ed) Hormonal manipulation of cancer: peptides, growth factors, and new (anti)steroidal agents. Raven, New YorkGoogle Scholar
  248. 248.
    Waxman JH, Sandow J, Abel P, Farah N, O’Donoghue EP, Fleming J, Cox J, Sikora K, Williams G (1989) Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol (Copenh) 120:315–318Google Scholar
  249. 249.
    Sandow J, Stoeckemann K, Jerabek-Sandow G (1990) Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. J Steroid Biochem Mol Biol 37:925–963PubMedGoogle Scholar
  250. 250.
    Behre HM, Sandow J, Nieschlag E (1992) Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. Arzneimittelforschung 42:80–84PubMedGoogle Scholar
  251. 251.
    Tamada J, Langer R (1992) The development of polyanhydrides for drug delivery applications. J Biomater Sci Polym Ed 3:315–353PubMedGoogle Scholar
  252. 252.
    Brem H, Gabikian P (2001) Biodegradable polymer implants to treat brain tumors. J Control Release 74:63–67PubMedGoogle Scholar
  253. 253.
    Greenstein G, Polson A (1998) The role of local drug delivery in the management of periodontal diseases: a comprehensive review. J Periodontol 69:507–520PubMedGoogle Scholar
  254. 254.
    Ravivarapu HB, Moyer KL, Dunn RL (2000) Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J Pharm Sci 89:732–741PubMedGoogle Scholar
  255. 255.
    Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC (2002) A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24:1902–1914PubMedGoogle Scholar
  256. 256.
    Dunn R, Garrett J, Ravivarapu H, Chandrashekar B (2003) Polymeric delivery formulations of leuprolide with improved efficacy. United States Patent US 6,565,874Google Scholar
  257. 257.
    Sartor O (2003) Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 61:25–31PubMedGoogle Scholar
  258. 258.
    Perez-Marrero I, Tyler RC (2004) A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 5:447–457PubMedGoogle Scholar
  259. 259.
    ICH (2003) Guidance for industry, Q3C impurities: Residual solvents. U.S. Department of Health and Human Services, Food and Drug Administration (FDA). and
  260. 260.
    Wang LW, Venkatraman S, Gan LH, Kleiner L (2005) Structure formation in injectable poly(lactide-co-glycolide) depots. II. Nature of the gel. J Biomed Mater Res B 72B:215–222Google Scholar
  261. 261.
    Lambert WJ, Peck KD (1995) Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins. J Control. Rel. 33:189–195Google Scholar
  262. 262.
    Wischke C, Zhang Y, Mittal S, Schwendeman S (2010) Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. Pharm. Res. 27:2063–2074Google Scholar

Copyright information

© Springer US 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesUniversity of MichiganAnn ArborUSA
  2. 2.Center for Biomaterial Development and Berlin-Brandenburg Center for Regenerative TherapiesHelmholtz-Zentrum GeesthachtTeltowGermany

Personalised recommendations